Leslie Trigg has sold stock and made no open-market buys since Jun 2016

Leslie Trigg is a corporate insider and individual executive serving as Chair and Chief Executive Officer of Outset Medical, Inc. (Nasdaq: OM), a medical device company focused on dialysis care.( She has been Outset Medical’s CEO since November 2014 and was elected Chair of the Board in 2022, overseeing the commercialization of the FDA‑cleared Tablo Hemodialysis System and the company’s transition to a publicly traded enterprise.(

Before joining Outset Medical from private equity firm Warburg Pincus as an Executive‑in‑Residence, Trigg held senior leadership roles across multiple medtech companies, including Executive Vice President at Lutonix (acquired by CR Bard), Chief Business Officer at AccessClosure (acquired by Cardinal Health), and Vice President of Marketing at FoxHollow Technologies, where she helped build the commercial strategy that led to an IPO and subsequent acquisition by ev3/Covidien.( Her earlier management experience includes positions at Cytyc Corporation and Pro‑Duct Health, Inc. (acquired by Cytyc), and she began her medical device career at Guidant Corporation.( Trigg also serves in broader industry leadership roles, including Board Chair of the Medical Device Manufacturers Association, and has previously held board seats at Adaptive Biotechnologies, Cardiovascular Systems, Inc., and ARYA Sciences Acquisition Corp IV.( She holds a Bachelor of Science degree from Northwestern University and an MBA from the Haas School of Business at the University of California, Berkeley.(

Written by Perplexity from public sources.